Ligand id: 7985

Name: durvalumab

No information available.
Summary of Clinical Use
Durvalumab (MEDI-4736) was 'fast tracked' to Phase 3 clinical trial, then receiving full FDA approval in May 2017 for the treatment of advanced/metastatic bladder cancer (urothelial carcinoma) in patients who have already received platinum-containing chemotherapy. It is hoped that durvalumab may show clinical efficacy against other cancers, including some lung cancers. Click here to link to ClinicalTrials.gov's list of Phase 2 and 3 studies evaluating MEDI-4736 in additional cancer types.
Mechanism Of Action and Pharmacodynamic Effects
Anti-PD-L1 antibodies interfere with PD-L1 signalling, which results in the activation of tumour-detecting/infiltrating T cells. The drug’s mechanism of action enables the immune cells to detect and destroy tumour cells.